Meeting
2023 ASCO Genitourinary Cancers Symposium
Treatment and survival of de novo metastatic prostate cancer in US veterans.
Authors
Martin W. Schoen
Saint Louis University School of Medicine, St. Louis, MO
Martin W. Schoen , Ruth Douglas Etzioni , Eric Marshall Knoche , Julie N Graff , Kristen Marie Sanfilippo , Suhong Luo , Seth A Eisen , Robert Bruce Montgomery
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 87)
DOI
10.1200/JCO.2023.41.6_suppl.87
Abstract #
87
Poster Bd #
C14
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of disease.
First Author: Martin W. Schoen
Poster
2024 ASCO Genitourinary Cancers Symposium
Clinical and patient factors associated with treatment intensification for metastatic castration-sensitive prostate cancer.
First Author: Sreevalsa Appukkuttan
Poster
2023 ASCO Genitourinary Cancers Symposium
Oncologists’ perspectives on metastatic hormone sensitive prostate cancer management.
First Author: Patrick Heckman
Poster
2024 ASCO Genitourinary Cancers Symposium
A systematic review: Are the findings of indirect treatment comparisons (ITCs) in metastatic hormone-sensitive prostate cancer (mHSPC) consistent?
First Author: Neal D. Shore